Post-transplant patients with COVID-19 associated acute respiratory distress syndrome, a role for Tociluzumab: A case series

2020

Wu, 2020, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China, JAMA Internal Medicine, 180, 934, 10.1001/jamainternmed.2020.0994

Grasselli, 2020, Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA., 323, 1574, 10.1001/jama.2020.5394

Gordon, 2020, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus, J. Biol. Chem., 295, 4773, 10.1074/jbc.AC120.013056

Yao, 2020

Yao, 2020, A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—a possible reference for coronavirus disease‐19 treatment option, J. Med. Virol., 92, 556, 10.1002/jmv.25729

Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 56, 10.1016/j.ijantimicag.2020.105949

Grein, 2020, Compassionate use of remdesivir for patients with severe covid-19, N. Engl. J. Med., 382, 2327, 10.1056/NEJMoa2007016

Cao, 2020, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, N. Engl. J. Med., 382, 1787, 10.1056/NEJMoa2001282

2020, ICNARC report on COVID-19 in critical care, Intensive Care National Audit & Research Centre (ICNARC)

Wan, 2020

McGonagle, 2020, The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease, Autoimmun. Rev., 10.1016/j.autrev.2020.102537

Bhatraju, 2020, Covid-19 in critically ill patients in the Seattle region—case series, N. Engl. J. Med., 382, 2012, 10.1056/NEJMoa2004500

Luo, 2020, Tocilizumab treatment in COVID‐19: a single center experience, J. Med. Virol., 92, 814, 10.1002/jmv.25801

Brower, 2000, Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome, N. Engl. J. Med., 342, 1301, 10.1056/NEJM200005043421801

Tang, 2020, Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, 369, m1849, 10.1136/bmj.m1849

Molina, 2020, No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection, Med. Maladies Infect., 50, 384, 10.1016/j.medmal.2020.03.006